172 related articles for article (PubMed ID: 38832421)
21. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
[TBL] [Abstract][Full Text] [Related]
22. In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.
Minagawa K; Jamil MO; Al-Obaidi M; Pereboeva L; Salzman D; Erba HP; Lamb LS; Bhatia R; Mineishi S; Di Stasi A
PLoS One; 2016; 11(12):e0166891. PubMed ID: 27907031
[TBL] [Abstract][Full Text] [Related]
23. CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype.
Li S; Tao Z; Xu Y; Liu J; An N; Wang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
Hum Gene Ther; 2018 May; 29(5):626-639. PubMed ID: 29409351
[TBL] [Abstract][Full Text] [Related]
24. CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity.
Sauer T; Parikh K; Sharma S; Omer B; Sedloev D; Chen Q; Angenendt L; Schliemann C; Schmitt M; Müller-Tidow C; Gottschalk S; Rooney CM
Blood; 2021 Jul; 138(4):318-330. PubMed ID: 34323938
[TBL] [Abstract][Full Text] [Related]
25. Finding new lanes: Chimeric antigen receptor (CAR) T-cells for myeloid leukemia.
Pratap S; Zhao ZJ
Cancer Rep (Hoboken); 2020 Apr; 3(2):e1222. PubMed ID: 32671999
[TBL] [Abstract][Full Text] [Related]
26. [Target Selection of CAR-T Therapy in Acute Myeloid Leukemia--Review].
Shao RN; Xin HL; Shi XF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Jun; 32(3):965-969. PubMed ID: 38926997
[TBL] [Abstract][Full Text] [Related]
27. Acute Myeloid Leukemia Targeting by Chimeric Antigen Receptor T Cells: Bridging the Gap from Preclinical Modeling to Human Studies.
Rotiroti MC; Arcangeli S; Casucci M; Perriello V; Bondanza A; Biondi A; Tettamanti S; Biagi E
Hum Gene Ther; 2017 Mar; 28(3):231-241. PubMed ID: 27967241
[TBL] [Abstract][Full Text] [Related]
28. Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia.
Lichtman EI; Du H; Shou P; Song F; Suzuki K; Ahn S; Li G; Ferrone S; Su L; Savoldo B; Dotti G
Clin Cancer Res; 2021 Jun; 27(11):3141-3153. PubMed ID: 33531429
[TBL] [Abstract][Full Text] [Related]
29. Chimeric Antigen Receptor-Modified T Cells and T Cell-Engaging Bispecific Antibodies: Different Tools for the Same Job.
Schwerdtfeger M; Benmebarek MR; Endres S; Subklewe M; Desiderio V; Kobold S
Curr Hematol Malig Rep; 2021 Apr; 16(2):218-233. PubMed ID: 33939108
[TBL] [Abstract][Full Text] [Related]
30. Recent advances in CAR-T cell therapy for acute myeloid leukaemia.
Gao C; Li X; Xu Y; Zhang T; Zhu H; Yao D
J Cell Mol Med; 2024 May; 28(9):e18369. PubMed ID: 38712978
[TBL] [Abstract][Full Text] [Related]
31. Case report: Donor-derived CLL-1 chimeric antigen receptor T-cell therapy for relapsed/refractory acute myeloid leukemia bridging to allogeneic hematopoietic stem cell transplantation after remission.
Miao X; Shuai Y; Han Y; Zhang N; Liu Y; Yao H; Wang X; He G; Chen D; Fan F; Chang AH; Su Y; Yi H
Front Immunol; 2024; 15():1389227. PubMed ID: 38803489
[TBL] [Abstract][Full Text] [Related]
32. B7-H3 chimeric antigen receptor-modified T cell shows potential for targeted treatment of acute myeloid leukaemia.
Fan S; Wang T; You F; Zhang T; Li Y; Ji C; Han Z; Sheng B; Zhai X; An G; Meng H; Yang L
Eur J Med Res; 2023 Mar; 28(1):129. PubMed ID: 36941687
[TBL] [Abstract][Full Text] [Related]
33. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
34. Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.
Badar T; Shah NN
Curr Treat Options Oncol; 2020 Feb; 21(2):16. PubMed ID: 32025828
[TBL] [Abstract][Full Text] [Related]
35. CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
Wagner J; Wickman E; DeRenzo C; Gottschalk S
Mol Ther; 2020 Nov; 28(11):2320-2339. PubMed ID: 32979309
[TBL] [Abstract][Full Text] [Related]
36. Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML).
Lu Y; Liu Y; Wen S; Kuang N; Zhang X; Li J; Wang F
J Transl Med; 2022 Dec; 20(1):600. PubMed ID: 36517851
[TBL] [Abstract][Full Text] [Related]
37. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.
Qu J; Mei Q; Chen L; Zhou J
Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047
[TBL] [Abstract][Full Text] [Related]
38. Recent progress in chimeric antigen receptor therapy for acute myeloid leukemia.
Wang X; Zhang Y; Xue S
Ann Hematol; 2024 Jun; 103(6):1843-1857. PubMed ID: 38381173
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of chimeric antigen receptor T-cell therapy for acute myeloid leukemia: A subgroup based meta-analysis.
Morsy MM; Azzam AY; Elamin O; Elswedy A; Nashwan AJ
Leuk Res; 2024 May; 140():107498. PubMed ID: 38582045
[TBL] [Abstract][Full Text] [Related]
40. Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia.
Arcangeli S; Rotiroti MC; Bardelli M; Simonelli L; Magnani CF; Biondi A; Biagi E; Tettamanti S; Varani L
Mol Ther; 2017 Aug; 25(8):1933-1945. PubMed ID: 28479045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
